Atlas Trials

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Clinical trial NCT03680560 · TERMINATED

Trial details

NCT number
NCT03680560
Sponsor
Cogent Biosciences, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid TumorHER-2 Protein Overexpression
Start date
2019-03-13
Primary completion
2020-03-12
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.